Published in Int J Cancer on March 15, 1990
Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A (2006) 4.66
DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines. PLoS One (2010) 1.65
Metallothionein protects DNA from oxidative damage. Biochem J (1993) 1.42
Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines. Mol Cancer Ther (2008) 1.28
Modulation of cis-diamminedichloroplatinum(II) resistance: a review. Br J Cancer (1992) 1.25
Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics. Proc Natl Acad Sci U S A (2010) 1.20
The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. Am J Pathol (2010) 1.07
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. Mol Oncol (2013) 1.00
Metallothionein expression in human breast cancer. Br J Cancer (1995) 0.95
Design, synthesis, and X-ray crystal structures of 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors. Bioorg Med Chem (2009) 0.94
Metallothionein induction in response to restraint stress. Transcriptional control, adaptation to stress, and role of glucocorticoid. J Biol Chem (1998) 0.92
A mutant mouse (tx) with increased hepatic metallothionein stability and accumulation. Biochem J (1993) 0.91
Dinuclear platinum anticancer complexes with fluorescent N,N'-bis(aminoalkyl)-1,4-diaminoanthraquinones: cellular processing in two cisplatin-resistant cell lines reflects the differences in their resistance profiles. J Biol Inorg Chem (2005) 0.86
Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents. Bioorg Med Chem (2008) 0.83
Metallothionein levels in ovarian tumours before and after chemotherapy. Br J Cancer (1991) 0.82
N⁴-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation. Bioorg Med Chem (2012) 0.81
Non-steroidal anti-inflammatory drugs decrease E2F1 expression and inhibit cell growth in ovarian cancer cells. PLoS One (2013) 0.81
Chemotherapeutic drug resistance in the management of head and neck cancer. Eur Arch Otorhinolaryngol (1993) 0.81
The cranberry flavonoids PAC DP-9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells. Int J Oncol (2015) 0.80
The contribution of a 2-amino group on receptor tyrosine kinase inhibition and antiangiogenic activity in 4-anilinosubstituted pyrrolo[2,3-d]pyrimidines. Bioorg Med Chem Lett (2010) 0.79
The human lung adenocarcinoma cell line EKVX produces an infectious xenotropic murine leukemia virus. Viruses (2011) 0.79
Cisplatin Resistant Spheroids Model Clinically Relevant Survival Mechanisms in Ovarian Tumors. PLoS One (2016) 0.79
The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells. Cancer Cell Int (2011) 0.78
Synthesis and evaluation of 5-(arylthio)-9H-pyrimido[4,5-b]indole-2,4-diamines as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents. Bioorg Med Chem Lett (2017) 0.75
Characterization of ovarian cancer cell lines as in vivo models for preclinical studies. Gynecol Oncol (2016) 0.75
New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst (1990) 23.46
A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell (1992) 19.87
An information-intensive approach to the molecular pharmacology of cancer. Science (1997) 11.43
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res (1988) 9.96
Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res (1988) 8.53
p53-mediated DNA repair responses to UV radiation: studies of mouse cells lacking p53, p21, and/or gadd45 genes. Mol Cell Biol (2000) 6.23
Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science (1994) 6.11
Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A (1987) 5.65
AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A (1992) 5.24
Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res (1985) 5.09
Repair of gamma-ray-induced DNA base damage in xeroderma pigmentosum cells. Radiat Res (1986) 5.08
Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst (1989) 4.97
Comparison of the effects of BRL 34915 and verapamil on electrical and mechanical activity in rat portal vein. Br J Pharmacol (1986) 4.75
Malaria on the move: human population movement and malaria transmission. Emerg Infect Dis (2000) 4.53
Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res (1997) 4.34
Virus-specific proteins synthesized in encephalomyocarditis virus-infected HeLa cells. Proc Natl Acad Sci U S A (1971) 4.20
The gadd and MyD genes define a novel set of mammalian genes encoding acidic proteins that synergistically suppress cell growth. Mol Cell Biol (1994) 4.15
Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst (1990) 4.08
Temperature-sensitive mutations in Drosophila melanogaster. XIV. A selection of immobile adults. Mol Gen Genet (1973) 3.85
The natural history of Hendra and Nipah viruses. Microbes Infect (2001) 3.77
Sequence analysis of the L1 metallo-beta-lactamase from Xanthomonas maltophilia. Biochim Biophys Acta (1994) 3.52
Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J (1999) 3.46
Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother (1997) 3.40
Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol (1994) 3.30
Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature (2001) 3.25
High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A (1992) 3.22
High level multiplex genotyping by MALDI-TOF mass spectrometry. Nat Biotechnol (1998) 3.22
Genomic instability in Gadd45a-deficient mice. Nat Genet (1999) 3.01
Developmental properties of Shibire: a pleiotropic mutation affecting larval and adult locomotion and development. Dev Biol (1973) 2.92
Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res (1983) 2.90
Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res (2000) 2.86
GADD45 induction of a G2/M cell cycle checkpoint. Proc Natl Acad Sci U S A (1999) 2.80
Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol Cell Biol (1993) 2.77
Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res (1987) 2.67
An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res (2000) 2.47
The p53-dependent G1 cell cycle checkpoint pathway and ataxia-telangiectasia. Cancer Res (1994) 2.41
Recognition of a peptide antigen by heat shock--reactive gamma delta T lymphocytes. Science (1990) 2.41
Infection of mouse fibroblasts by cardioviruses: premature uncoating and its prevention by elevated pH and magnesium chloride. Virology (1971) 2.39
Induction of B2 RNA polymerase III transcription by heat shock: enrichment for heat shock induced sequences in rodent cells by hybridization subtraction. Nucleic Acids Res (1986) 2.31
Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen. J Natl Cancer Inst (1998) 2.31
Fluorescent cDNA microarray hybridization reveals complexity and heterogeneity of cellular genotoxic stress responses. Oncogene (1999) 2.29
Evaluation of a brief psychological treatment for emotional disorders in primary care. Psychol Med (1991) 2.28
Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science (1984) 2.24
5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proc Natl Acad Sci U S A (1982) 2.19
Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst (1996) 2.17
Comparison of the nucleotide sequence of cloned human and guinea-pig pre-alpha-lactalbumin cDNA with that of chick pre-lysozyme cDNA suggests evolution from a common ancestral gene. Nucleic Acids Res (1982) 2.14
Association with Cdc2 and inhibition of Cdc2/Cyclin B1 kinase activity by the p53-regulated protein Gadd45. Oncogene (1999) 2.12
Identification of potential mRNA biomarkers in peripheral blood lymphocytes for human exposure to ionizing radiation. Radiat Res (2000) 2.11
Genetic variability between isolates of human immunodeficiency virus (HIV) type 2 is comparable to the variability among HIV type 1. Proc Natl Acad Sci U S A (1988) 2.07
Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res (1991) 2.06
p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res (1998) 2.02
The anthracycline antineoplastic drugs. N Engl J Med (1981) 2.02
Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res (1995) 2.00
Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage. Oncogene (1995) 2.00
Gadd45, a p53-responsive stress protein, modifies DNA accessibility on damaged chromatin. Mol Cell Biol (1999) 1.97
Development of human tumor cell line panels for use in disease-oriented drug screening. Prog Clin Biol Res (1988) 1.95
p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res (1994) 1.94
Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene (1994) 1.88
Efficacy of D0870 compared with those of itraconazole and amphotericin B in two murine models of invasive aspergillosis. Antimicrob Agents Chemother (1995) 1.86
Myc represses the growth arrest gene gadd45. Oncogene (1997) 1.86
Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol (1985) 1.86
Mammalian GADD34, an apoptosis- and DNA damage-inducible gene. J Biol Chem (1997) 1.85
Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. Biochemistry (1990) 1.83
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res (1996) 1.82
Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. J Natl Cancer Inst (1992) 1.82
BRL 34915, a novel antihypertensive agent: comparison of effects on blood pressure and other haemodynamic parameters with those of nifedipine in animal models. J Cardiovasc Pharmacol (1986) 1.79
T-cell growth factor: complete nucleotide sequence and organization of the gene in normal and malignant cells. Proc Natl Acad Sci U S A (1984) 1.77
Eukaryotic methionyl aminopeptidases: two classes of cobalt-dependent enzymes. Proc Natl Acad Sci U S A (1995) 1.76
Chemotherapy of ovarian cancer. Semin Oncol (1984) 1.75
The influence of volumetric tumor doubling time, DNA ploidy, and histologic grade on the survival of patients with intracranial astrocytomas. AJNR Am J Neuroradiol (1995) 1.74
Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer. J Clin Oncol (1992) 1.74
Response to adversity: molecular control of gene activation following genotoxic stress. New Biol (1991) 1.72
Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene (1998) 1.71
Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci U S A (1987) 1.71
Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol (1994) 1.70
Induction by ionizing radiation of the gadd45 gene in cultured human cells: lack of mediation by protein kinase C. Mol Cell Biol (1991) 1.69
Induction of gene expression as a monitor of exposure to ionizing radiation. Radiat Res (2001) 1.69
Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol (1995) 1.67
Amplification of DNA sequences in human multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci U S A (1985) 1.66
Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina (1996) 1.65
A nucleotide excision repair master-switch: p53 regulated coordinate induction of global genomic repair genes. Cancer Biol Ther (2002) 1.64
Leukemic HRX fusion proteins inhibit GADD34-induced apoptosis and associate with the GADD34 and hSNF5/INI1 proteins. Mol Cell Biol (1999) 1.62
The GADD45 inhibition of Cdc2 kinase correlates with GADD45-mediated growth suppression. J Biol Chem (2000) 1.62
The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis. J Natl Cancer Inst (1999) 1.61
Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. J Natl Cancer Inst (1992) 1.61
AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. Cancer Res (1998) 1.61
TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. J Immunol (2000) 1.60
Analysis of the mammalian gadd45 gene and its response to DNA damage. J Biol Chem (1993) 1.58
Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol (2000) 1.58
Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res (1988) 1.55